NEW TRIGLYCERIDE OBTAINED FROM A MACROCYBE TITANS EXTRACT, CLINICAL APPLICATIONS AND PRODUCTION METHOD

Abstract

The present invention relates to a new triglyceride, of the formula 2R-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z), extracted from an extract of the Macrocybe titans fungus. Likewise, its use as a medicine and its different clinical applications in the treatment of diseases regulated by the actin cytoskeleton are contemplated. Its use as an antitumoral agent in cancer diseases is mainly contemplated. Finally, the invention relates to the process for obtaining the Macrocybe titans extract that comprises the triglyceride of the invention.

Claims

1. Triglyceride of formula 2R-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z).

2. Triglyceride according to claim 1, for its use as a medicine.

3. Triglyceride according to claim 2 for its use in the treatment of diseases regulated by the actin cytoskeleton.

4. Triglyceride according to claim 3, wherein the disease regulated by the actin cytoskeleton is selected from amyloidosis, retinitis pigmentosa, infectious diseases, kidney diseases and congenital deafness syndrome.

5. Triglyceride according to claim 2, for its use in the treatment of cancer diseases.

6. Triglyceride according to claim 1 for its use in the diagnosis of tumors using imaging techniques.

7. Triglyceride according to claim 6 for its use in combination with a tracer.

8. Pharmaceutical composition comprising the triglyceride according to claim 1.

9. Macrocybe titans extract comprising the triglyceride of claim 1.

10. Procedure for obtaining an extract of Macrocybe titans according to claim 9 comprising the following steps: a. subjecting a sample of a Macrocybe titans fungus to an extraction in 95% ethanol, b. treating the extract obtained in a) with ultrasound for 30-60 minutes, c. maintaining the extract treated in b) at a temperature between −20 and −80° C., for 24-48 hours, d. obtaining the precipitated phase of the extract thus treated, and e. from the precipitated phase of the extract obtained in d), carrying out an alkaloid separation followed by a column chromatography with polymeric resin using an 8:2 IP:CH.sub.2L.sub.2 mobile phase at pH 12, leading to a fraction of the extract that comprises the triglyceride of claim 1.

Description

BRIEF DESCRIPTION OF FIGURES

[0005] FIG. 1. Toxicity analysis in lines A549 (tumor) and NL20 (non-tumor) with the initial extract of M. titans. IC.sub.50 for the tumor line <0.1 mg/ml; IC.sub.50 for the non-tumor line=0.5 mg/ml.

[0006] FIG. 2. .sup.1H-NMR spectrum of the purified extract. The typical protons of glycerol, those of alkyl and olefin groups, are indicated.

[0007] FIG. 3. .sup.13C-NMR spectrum of the purified extract. The typical carbons of glycerol, those of alkyl, olefin and carbonyl groups are indicated.

[0008] FIG. 4. A549 and NL20 cells stained with fluorescent falacidine that marks actin fibers (in green), before (Control) and after being treated (Treated) with TG10.

[0009] FIG. 5. Evolution of tumor volume in the xenograft experiment. Tumors injected with vehicle (Control, diamonds) or with TG10 (TG, squares). The mean of the volumes for each group over time is represented (d=days from the injection of the tumor cells).

DETAILED DESCRIPTION OF THE INVENTION

[0010] The authors of the present invention have identified from a Macrocybe titans fungus extract a new compound capable of stopping tumor growth in vivo.

[0011] A main aspect of the invention provides said compound, which is a triglyceride of formula 2R-TG (C18: 2, 9z, 12z; C16: 0; C18: 1, 9z), hereinafter TG10, represented by the following scheme:

##STR00001##

[0012] This compound acts as a biological response modifier (BRM) since it specifically alters the actin cytoskeleton. Therefore, it has direct applications in all those phenomena regulated by this component of the cytoskeleton, including in a non-exclusive way: i) changes in cell morphology, ii) cell motility (including metastasis), iii) muscle contraction, iv) modification of cell-cell junctions, v) regulation of endocytosis and phagocytosis, vi) embryogenesis, vii) control of gene expression, viii) regulation of the immune system, ix) defense against pathogens (bacteria, fungi, viruses, parasites, etc.) and x) regulation of apoptosis, among others.

[0013] Due to its properties, in a second aspect of the invention, the TG10 triglyceride of the invention is provided for use as a medicine.

[0014] The TG10 triglyceride positively influences all those diseases related to the actin cytoskeleton. Thus, another aspect of the invention provides the use of triglyceride in the treatment of actin cytoskeleton regulated diseases such as, but not limited to, amyloidosis, retinitis pigmentosa, infectious diseases, kidney diseases and congenital deafness syndrome.

[0015] The triglyceride of the invention has been shown to be effective in reducing the size of human tumors. Thus, another main aspect of the invention provides the use of TG10 triglyceride in the treatment of cancer diseases, both in animals and in human patients, by itself or in combination with other therapies (radiotherapy, chemotherapy, immunotherapy, etc.).

[0016] Furthermore, the authors of the present invention have shown that triglyceride binds preferentially to tumor cells, therefore, together with a tracer (fluorescent, radioactive, etc.), it allows locating tumors in a living organism, both in an animal as in a human patient, in the context of diagnostic imaging devices (PET, fluorescence, etc.). Said affinity of the triglyceride for tumor cells also allows drugs or nanoparticles to be directed towards tumor cells, as therapeutic treatments.

[0017] In another main aspect of the invention a pharmaceutical composition comprising the triglyceride of the invention is provided.

[0018] As mentioned above, the authors of the present invention obtained triglyceride from an extract of Macrocybe titans. Thus, another main aspect of the invention provides the procedure for obtaining an extract of Macrocybe titans that comprises the following steps: [0019] a. subjecting a sample of a Macrocybe titans fungus to an extraction in 95% ethanol, [0020] b. treating the extract obtained in a) with ultrasound for 30-60 minutes, preferably 30 min, [0021] c. maintaining the extract treated in b) at a temperature between −20 and −80° C., preferably −20° C., for 24-48 hours, preferably 24 hours, [0022] d. obtaining the precipitated phase of the extract thus treated, and [0023] e. from the precipitated phase of the extract obtained in d), carrying out an alkaloid separation followed by a column chromatography with polymeric resin using an 8:2 IP:CH.sub.2L.sub.2 mobile phase at pH 12, leading to a fraction of the extract that comprises the triglyceride of formula 2R-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z).

[0024] Once the triglyceride of the invention has been identified, and its formula determined, it is also possible to obtain it by means of its chemical synthesis, instead of extracting it from the original source, which has advantages from an economic, reproducibility and pharmacological safety point of view.

EXAMPLES

Examples 1. Iterative Screening by Toxicity Analysis and Separation of New Fractions by Chromatography

[0025] Extracts (aqueous, ethyl, acidic) were obtained from 9 macrofungi species collected by INBio in the Costa Rican rainforests. All of them were subjected to a cytotoxicity test with two human cell lines: A549 (lung adenocarcinoma) and NL20 (immortalized, non-tumor line, obtained from the pulmonary epithelium). Cells were plated in 96-well plates at densities of 2,000 (A549) or 10,000 (NL20) cells per well. Once the cells were stuck to the bottom, serial concentrations of each extract were added and incubated at 37° C. for 5 days under a humidified atmosphere (85% relative humidity) and containing 5% CO.sub.2. Eight repeats (wells) were studied for each concentration. At the end of the incubation process, 20 μl of Cell Titer (Promega) were added per well and left for 4 h to allow the formation of the colored formazan salts. Colorimetric quantification was performed with a plate reader (POLARstar Omega) using a wavelength of 490 nm, following already published protocols (Coderch C, Diaz de C M, Zapico J M, Pelaez R, Larrayoz I M, Ramos A, et al. In silico identification and in vivo characterization of small molecule therapeutic hypothermia mimetics. Bioorg Med Chem 2017; 25:6597-604). The selection criteria for the extracts consisted of choosing those with toxicity to tumor cells even at low concentrations while respecting the integrity of non-tumor cells, or at least providing a wide therapeutic window between both cell lines. The extracts selected in the first round were fractionated with different columns and chromatographic protocols. Each new peak was separated and subjected to toxicity analysis again. This process was repeated as many times as necessary to finally obtain a sufficiently pure fraction whose majority compound could be identified by analytical chemistry methods.

[0026] Results: Among all the extracts analyzed in the first round, the one corresponding to the M. titans species was the one with the widest therapeutic window since the A549 cells were destroyed at all concentrations, even at 0.1 mg/ml, while the NL20 cells survived without problems even at concentrations of 0.42 mg/ml (FIG. 1). Among the different extracts of this species, the most effective was that obtained by extraction in 95% ethanol, treated with ultrasound for 30 min, kept at −20° C. for 24 h and, specifically, the precipitated phase after this treatment. Due to the lipid nature of this extract, it was decided to perform an alkaloid separation followed by column chromatography with polymer resin (HP20-SS) using different mobile phases. All the fractions obtained were subjected to toxicity tests again. The fraction that maintained the best therapeutic window corresponded to that obtained at pH 12 and an 8: 2 IPA: CH.sub.2Cl.sub.2 mobile phase.

Example 2. Chemical Characterization of the Molecule Responsible for Antitumor Activity

[0027] The fraction obtained in the previous experiment was used to elucidate the chemical structure of the antitumor product. For this, nuclear magnetic resonance (NMR) analyzes with .sup.1H, .sup.13C and DEPT-135, mass spectroscopy (Q-TOF) and the two-dimensional HMQC and COSY experiments were performed.

[0028] Results: The .sup.1H-NMR study indicated that the product contained many alkyl protons, a series of α-protons to alcohols, and several olefin protons. The distribution of the protons indicated that the natural extract contained a triglyceride (TG) mixed with several of its component fatty acids. A triplet at 2.77 ppm recognized two protons of a methylene located between two double bonds, indicating a double unsaturation in one of the fatty acids (FIG. 2). The .sup.13C and DEPT-135 experiments allowed assigning the product carbons (FIG. 3). Two-dimensional experiments confirmed the assignment of carbons and protons in the TG. On the other hand, the exact mass determination (MS-QTOF) allowed identifying the fatty acids that made up the TG. All this led to suggest that the TG contained three different fatty acids: oleic (C18: 1, 9z), palmitic (C16: 0), and a doubly unsaturated fatty acid of 18 or 20 carbons. However, since the sample was not pure and it was difficult to accurately assign the order and size of the fatty acids, it was decided to synthesize a series of similar TGs to empirically determine the antitumor activity of each one. For some TGs that had optical activity, the two enantiomers were synthesized (Table 1). Toxicity tests indicated that of all TGs synthesized, only TG10 [2R-TG (C18: 2, 9z, 12z; C16: 0; C18: 1, 9z)] (FIG. 4) exhibited antitumor activity against A549 and it was not toxic to normal cells (NL20). The other TGs had no appreciable activity on the cells. It should be noted that the S enantiomer (TG9) of active TG (TG10) also had no effect on cells, indicating a high degree of specificity for this activity.

TABLE-US-00001 TABLE 1 Triglycerides (TG) synthesized to check its antitumor activity Internal code Formula TG1 TG (C16:0; C18:1, 9z; C20:2, 11z, 14z) TG2 TG (C16:0; C20:2, 11z, 14z; C18:1, 9z) TG3 TG (C16:0; C18:1, 9z; C18:1, 9z) TG4 TG (C18:2, 9z, 12z; C18:0; C18:1, 9z) TG5 2S-TG (C20:2, 11z, 14z; C18:1, 9z; C16:0) TG6 2R-TG (C20:2, 11z, 14z; C18:1, 9z; C16:0) TG7 2S-TG (C20:2, 11z, 14z; C16:0; C18:1, 9z) TG8 2R-TG (C20:2, 11z, 14z; C16:0; C18:1, 9z) TG9 2S-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z) TG10 (active) 2R-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z)

Example 3. In Vitro Tests: Modulation of the Actin Cytoskeleton

[0029] Many antitumor substances exert their effects by modulating the cytoskeleton of tumor cells, either acting on microtubules or on actin filaments (Zhang S, Menche D, Zahler S, Vollmer A M, Liebl J, Forster F. In vitro anti-cancer effects of the actin-binding natural compound rhizopodin. Pharmazie 2015; 70:610-5.). To check whether compound TG10 has a similar mechanism of action as other antitumor drugs, tumor cells (A549) and non-tumor cells (NL20) were subjected to a 24-hour treatment with 0.03 mg/ml TG10. At the end of this time, the cells were fixed with 10% formaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 10 min and exposed to 1: 200 Bodipy-falacidine and 1: 1000 DAPI (Molecular Probes) for 1 h. The images were obtained with a confocal laser microscope (TCS SP5, Leica).

[0030] Results: As expected, both A549 and NL20 cells have typical stress fibers (composed of actin filaments) in their cytoplasm before treatment. After TG10 treatment, A549 cells completely lost the polymerized actin fibers and this passed to the cell periphery, where small filopodia were formed. In contrast, NL20 (non-tumor) cells maintained the filamentous structure of actin even after TG10 treatment (FIG. 4). These results confirmed that TG10 acts on the actin cytoskeleton of tumor cells.

Example 4. In Vivo Assays: Human Lung Cancer Xenografts in Immunosuppressed Mice

[0031] The usual method of demonstrating that a new antitumor drug works in vivo is to perform a xenograft experiment using human tumor cells injected into immunodeficient mice (Zitvogel L, Pitt J M, Daillere R, Smyth M J, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer 2016; 16:759-73). In this case, 20 male mice of the NOD scid gamma strain (NSG, Stock No. 005557, The Jackson Laboratory) were used. All of them were injected subcutaneously with 10 million A549 cells and left for 2 weeks until the tumors became measurable. Two groups of 10 mice each were randomized and marked as control group (diamonds) and TG10-treated group (squares). From this point, intratumor injections with 100 μl of PBS (control group) or 0.1 mg/ml of TG10 in PBS (treated group) were applied 3 times per week. Before each injection, tumor volumes were measured with a caliper. The mice were euthanized when the tumors reached a size incompatible with animal welfare.

[0032] Results: TG10 injections started on day 15 after the initial injection of tumor cells. From this point on, the size of the tumors injected with PBS continued to grow gradually until reaching the maximum size allowed (for reasons of ethics and animal welfare) on day 48. On the other hand, the tumors injected with TG10 continued to grow, but at a slower rate than that of the tumors of the control group (FIG. 5). At the end of the experiment, the tumors of the control group had an average volume of 2900 mm.sup.3, while those treated had an average volume of 1600 mm.sup.3. A two-way analysis of variance (ANOVA) was performed which showed that there is a significant difference between the volume of the treated tumors and the control ones (p<0.05) due to the treatment.